A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma

Required: BCMA (TNFRSF17) expression (expression on MM cells by flow cytometry or immunohistochemistry)

BCMA expression on MM cells determined by flow cytometry or immunohistochemistry

Must have received: anti-myeloma therapy

Previously treated with at least 2 lines of anti-MM therapy, with at least 1 complete treatment cycle for each line, and disease progression within 12 months after the most recent anti-myeloma treatment

Cannot have received: targeted therapy, epigenetic therapy, other investigational drugs, or treatment using invasive investigational medical devices

Received targeted therapy, epigenetic therapy, other investigational drugs, or treatment using invasive investigational medical devices within 5 half-lives

Cannot have received: immune/non-immune-directed systemic therapy

Received immune/non-immune-directed systemic therapy within 1 week

Cannot have received: cytotoxic therapy

Received cytotoxic therapy within 1 week

Cannot have received: proteasome inhibitor

Received proteasome inhibitors or immunomodulatory agent therapy within 2 weeks

Cannot have received: immunomodulatory drug

Received proteasome inhibitors or immunomodulatory agent therapy within 2 weeks

Cannot have received: radiation therapy

Exception: if the radiation field covered ≤5% of bone marrow reserve, the subject is eligible regardless of the date of radiotherapy completion

Received radiotherapy within 4 weeks (if the radiation field covered ≤5% of bone marrow reserve, the subject is eligible regardless of the date of radiotherapy completion)

Cannot have received: allogeneic hematopoietic stem cell transplant

Received allogeneic HSCT within 6 months prior to infusion

Cannot have received: autologous hematopoietic stem cell transplant

autologous HSCT within 3 months prior to infusion

Cannot have received: viral therapy using VSVG pseudotype virus

Previously treated with any viral therapy using VSVG pseudotype virus